Company: TELO
Filing Date: 2025-11-24
Form Type: 8-K
Source: 0001493152-25-024818
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-24
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

PSA
is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related
manner.

The
Company is reporting new preclinical findings for Telomir-1. In an in vitro study conducted in androgen-responsive human prostate cancer
cells (LNCaP), Telomir-1 was observed to reduce prostate-specific antigen (“ PSA”) levels in a dose-related manner. PSA
is a protein released by prostate cancer cells, and higher levels generally indicate more active tumor behavior; it is widely used as
an FDA-recognized biomarker in prostate cancer studies.

The
Company is also providing additional context from previously reported preclinical work in a mouse model implanted with human aggressive,
non-androgen-related prostate cancer cells (PC3 xenograft). In that model, Telomir-1 reduced tumor volume when administered as a single
agent. In a combination cohort with paclitaxel, a full reduction in tumor volume was observed with no treatment-related mortality. Paclitaxel
alone produced a full reduction in tumor volume but was associated with a high mortality rate in that study cohort.

The
Company continues its preclinical development of Telomir-1 across oncology, aging biology, autism-related pathways, and other age-associated
conditions, and is advancing regulatory IND-enabling activities in preparation for its planned IND submission.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                TELOMIR PHARMACEUTICALS, INC.                               
  Dated: November 24, 2025      By:                                /s/                      
                                Name:                              Erez Aminov              
                                Title:                             Chief Executive Officer